Article

Efficacy and safety of a modified dosage regimen of nesiritide in patients older than 75 years with acute heart failure.

Department of Geriatric Cardiology, Chinese PLA General Hospital, China.
Aging - Clinical and Experimental Research (Impact Factor: 1.01). 03/2012; DOI: 10.3275/8295
Source: PubMed

ABSTRACT Background and Aims: To explore efficacy and safety of a modified dosage regimen of nesiritide in patients (≥75 years) with acute heart failure (AHF). Methods: Total 140 patients (≥75 years) with AHF were enrolled in this study. They were randomly and evenly divided into two group- control and nesiritide group. The control group received only conventional treatment for AHF, while the nesiritide group received conventional treatment plus a continual intravenous infusion of nesiritide at a rate of 0.0075~0.015 µg•kg-1•min-1 for 10-15 hours (total 0.5-1.0 mg) once daily for 13 days. Results: Medical research council scales in nesiritide group were significantly lower than those in control group on day 4, 8 and 14. Scores of edema had no significant difference, but were lower in nesiritide group on day 8 and 14. The nesiritide group had markedly more net body fluid losses. NT-proBNP, serum creatinine, blood pressure, cTnI, 30-day and 60-day mortality had no significant difference between two groups. Conclusions: Nesiritide resulted in improvements in dyspnea and edema, and similar adverse effects compared with conventional treatment. In spite of no reduction on short-term mortality and a reversible influence on renal function, nesiritide was still an important chioce for the elderly (≥75 years) with AHF.

0 Bookmarks
 · 
78 Views